Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,922,987 papers from all fields of science
Search
Sign In
Create Free Account
PSMA-targeted Docetaxel Nanoparticles BIND-014
Known as:
BIND-014
A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Microtubule Process
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
Hongliang He
,
Lisha Liu
,
E. Morin
,
Min Liu
,
A. Schwendeman
Accounts of Chemical Research
2019
Corpus ID: 201099162
In 1995, the year the first cancer nanomedicine, Doxil, was approved by the Food and Drug Administration (FDA), only 23…
Expand
Review
2018
Review
2018
PLGA-Based Nanoparticles in Cancer Treatment
Sima Rezvantalab
,
N. Drude
,
+5 authors
F. Kiessling
Frontiers in Pharmacology
2018
Corpus ID: 53199982
Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and…
Expand
Highly Cited
2018
Highly Cited
2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial
K. Autio
,
R. Dreicer
,
+13 authors
H. Scher
JAMA Oncology
2018
Corpus ID: 49698869
Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)–targeted nanoparticles is…
Expand
Review
2018
Review
2018
Advances in thermosensitive polymer-grafted platforms for biomedical applications.
P. Le
,
Chan-Khon Huynh
,
N. Tran
Materials Science and Engineering C: Materials…
2018
Corpus ID: 52165062
Highly Cited
2016
Highly Cited
2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
D. V. Von Hoff
,
M. Mita
,
+11 authors
J. Sachdev
Clinical Cancer Research
2016
Corpus ID: 13100268
Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel…
Expand
Review
2015
Review
2015
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
E. Alphandéry
,
Pierre Grand-Dewyse
,
Raphael Lefèvre
,
Chalani Mandawala
,
Mickaël Durand-Dubief
Expert Review of Anticancer Therapy
2015
Corpus ID: 32494977
Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical…
Expand
Review
2014
Review
2014
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
N. Bertrand
,
Jun Wu
,
Xiaoyang Xu
,
N. Kamaly
,
O. Farokhzad
Advanced Drug Delivery Reviews
2014
Corpus ID: 27145743
Review
2014
Review
2014
Targeted therapy using nanotechnology: focus on cancer
V. Sanna
,
N. Pala
,
M. Sechi
International Journal of Nanomedicine
2014
Corpus ID: 1299910
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as…
Expand
Highly Cited
2012
Highly Cited
2012
First plant-made biologic approved
J. Fox
Nature Biotechnology
2012
Corpus ID: 30936119
The US Food and Drug Administration in May approved Elelyso (taliglucerase alfa), an enzyme produced in genetically engineered…
Expand
Review
2011
Review
2011
Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Jinjun Shi
,
Zeyu Xiao
,
N. Kamaly
,
O. Farokhzad
Accounts of Chemical Research
2011
Corpus ID: 36242945
Nanoparticles (NPs) have become an important tool in many industries including healthcare. The use of NPs for drug delivery and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE